A control clinicial trial of a new anxiolytic 'clobazam'

Clobazam as a twice-a-day dosage (10 mg-20 mg) regimen and Diazepam in a thrice-a-day schedule (5 mg-5 mg-5 mg) were both effective in controlling moderate to severe anxiety neurosis. 83 patients were studied in a controlled, randomised, double-blind trial. Patients received active drug for the first six weeks and placebo for the next two weeks. Weekly evaluation was performed clinically for anxiolytic effect as well as effect on motor coordination studied on the Pursuit Rotor. Clobazam did not significantly differ from Diazepam in the dosage schedules studied. At the end of the two-week placebo treatment period, patients on Clobazam showed more improvement. Motor coordination was not impaired in both treatment groups. Clobazam treated patients had better motor performance at the end of the 14-day post-treatment placebo period. Side effects were reported with equal frequency in both the populations.